Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy
Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)
DOI: 10.1128/aac.00665-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Hamza Sayadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
Dalbavancin is increasingly used off-label for prolonged therapy in gram-positive infections, but optimal repeat-dosing strategies remain undefined, and published population pharmacokinetic (popPK) models lack external validation in real-world cohorts. A popPK model was developed using routine therapeutic drug monitoring (TDM) data from 183 adults (406 concentrations) with gram-positive infections and externally validated in an independent cohort ( n = 30, 92 concentrations). Predictive performance was benchmarked against five published models and a model averaging (MA) approach under three scenarios: a priori prediction and Bayesian forecasting with one or two TDM measurements. Monte Carlo simulations assessed the probability of target attainment ( f AUC 24 /MIC ≥111.1) for repeat-dose regimens (1,500 mg D1/D8 and D1/D15) at MICs 0.125 and 0.250 mg/L. A two-compartment model with eGFR (clearance) and body weight (clearance and volumes) best described the data. In a priori external validation, it achieved the lowest rRMSE (49.8%) among published models. MA with two TDM measurements yielded optimal performance (rRMSE 26.9%), closely followed by our model (31.4%). Simulations showed that empirical regimens maintained target attainment of ≥90% for 3–7 weeks, heavily dependent on PD targets and patient characteristics. A third 1,500 mg dose, timed to target decline, restored prolonged coverage across all strata. This externally validated popPK model, complemented by MA, provides robust pharmacokinetic foundations for precision dosing in gram-positive infections requiring prolonged therapy. Based on these findings, we propose an investigational sequential precision dosing workflow integrating machine learning with Bayesian forecasting; prospective validation is required before clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Pharmacovigilance, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
- Pharmacology & Transplantation, INSERM U1248, University of Limoges, Limoges, France.
- Clinical Pharmacology Department, Nantes University, Nantes University Hospital, Nantes, France.
- Infection and Immunity: Targets and Drugs, IICiMed, UR 1155, Nantes University, Nantes University Hospital, Nantes, France.
- INSERM CIC 1435, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
- Department of Infectious and Tropical Diseases, Dupuytren University Hospital (CHU Dupuytren), Limoges, France.
ORCID-Profile: Matthieu Gregoire, Jean-Baptiste Woillard
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Sayadi, H., Gregoire, M., Fromage, Y., Labriffe, M., Maizaud, F., Monchaud, C., Codde, C., Boutoille, D., Marquet, P., & Woillard, J. B. (2026). Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00665-26
Vancouver
Sayadi H, Gregoire M, Fromage Y, Labriffe M, Maizaud F, Monchaud C, et al. Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00665-26
BibTeX
@article{Sayadi2026,
author = {Sayadi, Hamza and Gregoire, Matthieu and Fromage, Yeleen and Labriffe, Marc and Maizaud, Franck and Monchaud, Caroline and Codde, Cyrielle and Boutoille, David and Marquet, Pierre and Woillard, Jean-Baptiste},
title = {Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {8},
doi = {10.1128/aac.00665-26}
}
EUVIMED